CS-Keys, an Indianapolis-based developer of cancer-specific biomarkers, has raised $6.25 million in Series A funding. Triathlon Medical Ventures led the deal, and was joined by Clarian Health Ventures, Prolog Venture, Ceres Venture Fund and Spring Mill Venture Partners.
CS-Keys, an Indianapolis-based company creating cancer-specific biomarkers using advanced proteomics for diagnostic and therapeutic applications, announced that it has closed on $6.25 million of Series A financing. Triathlon Medical Ventures, which seed funded the company, led the financing round. The funding marks two notable mentions: it is the first investment by the newly formed Clarian Health Ventures, and two venture capital firms with their first investments in Indiana also joined the financing